You are here: Home » News-CM » Companies » News
Business Standard

Alembic Pharmaceuticals receives ANDA approval for Fenofibric Acid Delayed-Release Capsules

Capital Market 

From USFDA

Alembic Pharmaceuticals announced that the Company has received approval from the US Food & Drug Administration for its Abbreviated New Drug Application for Fenofibric Acid Delayed-Release Capsules, 45 mg and 135 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product Trilipix Delayed Release Capsules, 45 mg and 135 mg of Abbvie Inc.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU